論文原著

英　文

• Yoda M, Kamei Y, Sakurai H, Kakei H, Tao T, Yamanouchi H, Kunikata T, Hariyama M, Colman R, Koshiba M.
  A Common Marmoset Model of Mother-Infant Intervention for Breastfeeding Disorders in the Presence of Paternal Inhibition and Maternal Neglect.
  J Vis Exp. 2023 Sep 22;(199). doi: 10.3791/64232.

• Itakura A, Shoji S, Shigeru A, Kotaro F, Junichi H, Hironobu H, Kamei Y, Eiji K, Shintaro M, Ryu M, Mamoru M, Takeshi N, Masahiko N, Naruse K, Hidekazu N, Tomizo N, Mana OY, Yasumasa O, Kuniaki O, Koichiro S, Arihiro S, Shunji S, Kanji T, Shiro Y, Yoshiki K, Tsugio M, Makio S.
  Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition.
  J Obstet Gynaecol Res. 49(1): 5-53, 2023
• Ito K, Go Y, Tatsumoto S, Usui C, Mizuno Y, Ikami E, Isozaki Y, Usui M, Kajihara T, Yoda T, Inoue KI, Takada M, Sato T.
  Gene expression profiling of the masticatory muscle tendons and Achilles tendons under tensile strain in the Japanese macaque Macaca fuscata.
  PLoS One. 2023 Jan 19;18(1):e0280649. doi: 10.1371/journal.pone.0280649. eCollection 2023.
• Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D; KEYNOTE-826 Investigators.
  First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
  J Clin Oncol. 41(36): 5505-5511, 2023
• Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K.
  Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
  J Clin Oncol. 41(15): 2789-2799, 2023.
• Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D.
  Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
  Lancet Oncol. 24(4): 392-402, 2023
• Sghaier S, Corbaux P, Ray-Coquard I, Lim MC, Hasegawa K, Nieuwenhuysen EV, Gonzalez A, Raspagliesi F, Freyer G.
  NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
  Future Oncol. 19(25): 1715-1727, 2023
• Isoda L, Sonoda-Fukuda E, Fujino H, Takarada T, Hasegawa K, Kasahara N, Kubo S.
  Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
  Anticancer Res. 43(12): 5311-5317, 2023
• Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, Makker V.
  Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
  Oncologist. 2023 Jul 31:oyad201. doi: 10.1093/oncolo/oyad201. Online ahead of print.
• Ishida M, Sato S, Sato I, Yoshioka A, Uchida N, Mizunuma N, Hasegawa K, Onishi H.
  What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder.
  Palliat Support Care. 2023 Jul 27:1-4. doi: 10.1017/S1478951523001128. Online ahead of print.
• Takeda A, Kobayashi M, Hasegawa K, Fujimaki T.
  Regression of Acoustic Tumor After Chemotherapy for Ovarian Cancer in a Patient With a Breast Cancer Susceptibility Gene 1 (BRCA1) Germline Mutation.
  Cureus. 2023 Mar 8;15(3):e35917. doi: 10.7759/cureus.35917. eCollection 2023 Mar.
• Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
  Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
  JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.
• Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinieri S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
  Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
  Eur J Cancer. 2023 Mar;181:42-52. doi: 10.1016/j.ejca.2022.11.029. Epub 2022 Dec 10.
• Onuki M, Takahashi F, Iwata T, Nakazawa H, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Mori-Uchino M, Kukimoto I, Fujii T, Watanabe Y, Noda K, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group.
  Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study.
  Cancer Sci. 114(11): 4426-4432, 2023
• Yoshida H, Fujiwara K.
  Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer.
  Cancer Med. 12(13): 14196-14206, 2023
• Monk BJ, Fujiwara K, O’Malley DM, Coleman RL, McNeish IA, Lin KK, Hume S, Kristeleit RS.
  Reply to C. Marchetti et al.
  J Clin Oncol. 41(4): 936-938, 2023
• Christinat Y, Ho L, Clément S, Genestie C, Sehouli J, Cinieri S, Gonzalez Martin A, Denison U, Fujiwara K, Vergote I, Tognon G, Hietanen S, Ray-Coquard I, Pujade-Lauraine E, McKee TA.
  Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
  JCO Precis Oncol. 2023 Jun;7:e2200555. doi: 10.1200/PO.22.00555.
• Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT).
  The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization.
  J Gynecol Oncol. 2023 Mar;34(2):e33. doi: 10.3802/jgo.2023.34.e33.
• Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT).
  The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization.
  Int J Gynecol Cancer. 33(4): 628-630, 2023
• Kajimoto Y, Honda K, Suzuki S, Mori M, Tsubouchi H, Nakao K, Azuma A, Shibutani T, Nagao S, Koyanagi T, Kohara I, Tamaki S, Yabuki M, Teng L, Fujiwara K, Igarashi A.
  Association between financial toxicity and health-related quality of life of patients with gynecologic cancer.
  Int J Clin Oncol. 28(3): 454-467, 2023
• Kohara I, Fujiwara N, Tamaki S, Nakahama H, Nosaki A, Hosoya M, Yabuki M, Yamamoto M, Kojima C, Fujiwara K.
  Development of a Japanese Scale that Evaluates the Level of Nursing Support Provided to Patients for Decision-Making in Cancer Clinical Trials.
  J Cancer Educ. 38(5): 1548-1556, 2023
• Herzog TJ, Pignata S, Ghamande SA, Rubio MJ, Fujiwara K, Vulsteke C, Armstrong DK, Sehouli J, Coleman RL, Gabra H, Scambia G, Monk BJ, Arranz JA, Ushijima K, Hanna R, Zamagni C, Wenham RM, González-Martín A, Slomovitz B, Jia Y, Ramsay L, Tewari KS, Weil SC, Vergote IB.
  Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
  Gynecol Oncol. 170: 300-308, 2023
• Matsumoto K, Sunaga Y, Ecstein-Fraisse E, Fujiwara K.
  Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors.
  Int J Gynecol Cancer. 2023 Nov 20:ijgc-2022-003880. doi: 10.1136/ijgc-2022-003880. Online ahead of print.
• Lorusso D, Colombo N, Herraez AC, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Kim YM, McCormack M, Massaad R, Nguyen AM, Zhao Q, McKenzie J, Prabhu VS, Makker V.
  Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice.
  Eur J Cancer. 186: 172-184, 2023
• Takahashi K, Samura O, Hasegawa A, Okubo H, Morimoto K, Horiya M, Okamoto A, Ochiai D, Tanaka M, Sekiguchi M, Miyasaka N, Suzuki Y, Tabata T, Hayata E, Nakata M, Suzuki T, Nishi H, Toda Y, Tanigaki S, Furuya N, Hasegawa J, Tamaru S, Kamei Y, Sayama S, Nagamatsu T, Takahashi YO, Kitagawa M, Arakaki T, Sekizawa A.
  COVID-19 mRNA vaccination status and concerns among pregnant women in Japan: a multicenter questionnaire survey.
  BMC Pregnancy Childbirth. 2023 May 9;23(1):332. doi: 10.1186/s12884-023-05669-4.
• Jwa SC, Goto R, Maeda E, Kajihara T, Ishihara O.
  Model-based estimation of the health care expenditure and out-of-pocket payment for assisted reproductive technology: A retrospective linkage study using the Japanese national ART registry.
  J Obstet Gynaecol Res. 49(7): 1778-1786, 2023
• Jwa SC, Takahashi H, Tamaru S, Takamura M, Namba A, Kajihara T, Ishihara O, Kamei Y.
  Assisted reproductive technology-associated risk factors for retained products of conception.
  Fertil Steril. 2023 Nov 28:S0015-0282(23)02024-1. doi: 10.1016/j.fertnstert.2023.11.028. Online ahead of print.
• Jwa SC, Kuwahara A, Ishihara O, Fujiwara H.
  Impact of COVID-19 pandemic on assisted reproductive technology treatment under voluntary lockdown in Japan.
  Reprod Med Biol. 2023 Sep 25;22(1):e12541. doi: 10.1002/rmb2.12541. eCollection 2023 Jan-Dec.
• Nagao S, Tamura J, Shibutani T, Miwa M, Kato T, Shikama A, Takei Y, Kamiya N, Inoue N, Nakamura K, Inoue A, Yamamoto K, Fujiwara K, Suzuki M.
  Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.
  Int J Clin Oncol. 28(6): 804-815, 2023
• Yagishita S, Nishikawa T, Yoshida H, Shintani D, Sato S, Miwa M, Suzuki M, Yasuda M, Ogitani Y, Jikoh T, Yonemori K, Hasegawa K, Hamada A.
  Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy.
  Clin Cancer Res. 29(12): 2239-2249, 2023

邦　文

• 左　勝則、田村早希、霞澤　亘、山口　哲、霞澤　匠、鷹野夏子、宮崎加寿子、田丸俊輔、難波　聡、亀井良政
  「生殖補助医療と周産期医療の連携」　ARTレジストリーを用いた経腟分娩後の癒着胎盤の合併に関連する要因の探索
  日本周産期・新生児医学会雑誌58(4): 938-940, 2023

論文総説

邦　文

• 亀井良政
  【周産期医療のヒヤリ・ハット-医療事故・医療紛争を防ぐために　産科編】無痛分娩における事故防止
  周産期医学53(6): 939-942, 2023
• 亀井良政
  【－豊富な所見で診断の進め方がわかる－産婦人科 画像診断アトラス】周産期-基本的スクリーニング　画像診断の進め方　妊娠初期のスクリーニング
  臨床婦人科産科77(4): 46-51, 2023
• 亀井良政
  【図表・チャートでパッと理解！ ここまでわかった産婦人科の病態生理】（第1章）周産期　D.産褥　劇症型溶血性連鎖球菌感染症（A群溶血性連鎖球菌感染症）
  産科と婦人科90(Suppl): 149-153, 2023
• 亀井良政
  【少産時代に対応する「働き方改革」と医療施設】一般分娩施設での対応　無痛分娩導入施設の実状と将来展望
  周産期医学53(2): 206-208, 2023
• 長谷川幸清
  子宮体癌　婦人科がんにおける免疫療法の現在
  クリニシアン70(1): 43-54, 2023
• 小笠原仁子、長谷川幸清
  【専攻医必携！　免疫チェックポイント阻害薬が変える子宮がん診療】総論　免疫チェックポイント阻害薬の作用機序
  臨床婦人科産科77(9): 854-859, 2023
• 永田一郎
  [FOCUS] 経腟的骨盤臓器脱手術の主柱（LevelⅠの修復法）としての仙骨子宮靭帯固定術
  臨床婦人科産科77(6): 630-637, 2023
• 永田一郎
  特別講演：改めて考える産婦人科手術の基本・開腹手術・腟式手術―鏡視下手術世代での役割―
  産婦人科手術34: 89-99, 2023
• 藤原恵一
  【国際共同試験への課題－がん化学療法におけるアジアと欧米の違い－】婦人科癌領域における国際共同試験への取り組み　Since 1997
  癌と化学療法50(1): 35-38, 2023
• 藤原恵一
  Gynecologic Cancer 婦人科腫瘍 進行卵巣癌初回化学療法を再考察しよう 総括
  癌と化学療法50 (2): 151-152, 2023.
• 田丸俊輔
  【産婦人科における先端情報処理技術の展開】遠隔胎児管理の実用化に向けた取り組み
  HORMONE FRONTIER IN GYNECOLOGY 30(2): 123-127, 2023
• 田丸俊輔
  【周産期の”絶対”ハズせないキーワード31　2023編　明日からの助産ケアに生かせる！】《分娩》CTG（胎児心拍数モニタリング）
  ペリネイタルケア42(4): 341-343, 2023
• 黒崎　亮
  婦人科腫瘍　進行卵巣癌初回化学療法を再考察しよう　最適なPARP阻害剤の使用法は？
  癌と化学療法50(2): 165-170, 2023
• 高橋幸子
  【今、改めて考える、流産、死産、新生児死亡】性教育の実践と課題
  周産期医学53(5): 753-757, 2023
• 高橋幸子
  【これからの性教育－タブー視せずにポジティブに捉える－】性教育の実際　#つながるBOOKの活用
  産科と婦人科90(8): 861-865, 2023
• 新谷大輔、長谷川幸清
  子宮体がんに対する免疫療法の進展
  腫瘍内科31(3): 393-398, 2023